MorphoSys (MOR) PT Set at €110.00 by JPMorgan Chase & Co.

MorphoSys (ETR:MOR) has been given a €110.00 ($127.91) price target by research analysts at JPMorgan Chase & Co. in a report issued on Wednesday. The brokerage currently has a “buy” rating on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 1.76% from the stock’s current price.

Other analysts also recently issued reports about the stock. Commerzbank set a €98.00 ($113.95) price target on shares of MorphoSys and gave the company a “buy” rating in a report on Thursday, July 19th. Oddo Bhf set a €110.00 ($127.91) price target on shares of MorphoSys and gave the company a “buy” rating in a report on Thursday, July 19th. Berenberg Bank set a €103.00 ($119.77) price target on shares of MorphoSys and gave the company a “buy” rating in a report on Thursday, August 2nd. Independent Research set a €120.00 ($139.53) price target on shares of MorphoSys and gave the company a “neutral” rating in a report on Tuesday, August 7th. Finally, Deutsche Bank set a €120.00 ($139.53) price target on shares of MorphoSys and gave the company a “neutral” rating in a report on Monday, August 6th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of €96.40 ($112.09).

Shares of ETR MOR opened at €108.10 ($125.70) on Wednesday. MorphoSys has a 52-week low of €49.63 ($57.71) and a 52-week high of €88.10 ($102.44).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Read More: Should You Consider an Index Fund?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply